Markets:

Overview

News

Currencies

International

Treasuries

Insulet Corporation - Common Stock (NQ:PODD)

165.35 -0.33 (-0.20%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

24 25 Next >

This Saia Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday ↗

April 29, 2025

Via Benzinga

1 Healthcare Stock Worth Your Attention and 2 to Turn Down

April 28, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and...

Via StockStory

Topics Stocks

Insulet Appoints Ashley McEvoy President and CEO

April 28, 2025

From Insulet Corporation

Via Business Wire

INSULET CORP (NASDAQ:PODD) qualifies as a high growth stock and is consolidating. ↗

April 25, 2025

Based on fundamental and technical analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD): a strong growth stock preparing for the next leg up?.

Via Chartmill

What's Driving the Market Sentiment Around Insulet? ↗

February 28, 2025

Via Benzinga

Thursday's pre-market session: top gainers and losers in the S&P500 index ↗

April 24, 2025

Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.

Via Chartmill

$100 Invested In Insulet 15 Years Ago Would Be Worth This Much Today ↗

April 22, 2025

Via Benzinga

What's Driving the Market Sentiment Around Insulet? ↗

April 14, 2025

Via Benzinga

BD, Teleflex, Insulet, UFP Technologies, and Haemonetics Shares Are Falling, What You Need To Know

April 10, 2025

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White House clarified the tariffs on imports from China would add up to 145%,...

Via StockStory

Topics Economy Government World Trade

Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)

April 08, 2025

Let’s dig into the relative performance of Masimo (NASDAQ:MASI) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.

Via StockStory

Topics Artificial Intelligence

Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry ↗

April 04, 2025

Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies...

Via Benzinga

Topics Government World Trade

Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock? ↗

April 03, 2025

Based on a technical and fundamental analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD)—A High-Growth Stock Gearing Up for Its Next Upward Move.

Via Chartmill

Insulet to Announce First Quarter 2025 Financial Results on May 8, 2025

April 03, 2025

From Insulet Corporation

Via Business Wire

Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks

April 03, 2025

Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers.

Via StockStory

Topics Artificial Intelligence

3 Reasons Investors Love Insulet (PODD)

March 27, 2025

Over the past six months, Insulet has been a great trade. While the S&P 500 was flat, the stock price has climbed by 14.6% to $265.87 per share. This was partly due to its solid quarterly results, and...

Via StockStory

Topics Stocks

Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today ↗

March 21, 2025

Via Benzinga

Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers

March 21, 2025

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season.

Via StockStory

Topics Artificial Intelligence

Insulet’s RADIANT Trial Demonstrates Meaningful Glycemic Improvements with the Omnipod® 5 Automated Insulin Delivery System Following Direct Transition from Multiple Daily Injections

March 19, 2025

From Insulet Corporation

Via Business Wire

Insulet Announces Pricing of Senior Notes Due 2033

March 18, 2025

From Insulet Corporation

Via Business Wire

Insulet Announces Proposed Financing Transactions

March 18, 2025

From Insulet Corporation

Via Business Wire

Insulet Expands Omnipod® 5 to Four More International Markets

March 18, 2025

From Insulet Corporation

Via Business Wire

From Injections to Innovation – Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod® 5 in Adults and Children with Type 1 Diabetes

March 18, 2025

From Insulet Corporation

Via Business Wire

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

March 14, 2025

Via Benzinga

Insulet to Host Investor Day on June 5, 2025

March 11, 2025

From Insulet Corporation

Via Business Wire

Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)

March 11, 2025

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest...

Via StockStory

Topics Artificial Intelligence

Exploring the Growth Potential of INSULET CORP (NASDAQ:PODD) as It Nears a Breakout. ↗

March 03, 2025

Based on fundamental and technical analysis of NASDAQ:PODD we conclude: INSULET CORP (NASDAQ:PODD): a strong growth stock preparing for the next leg up?.

Via Chartmill

1 Mid-Cap Stock on Our Watchlist and 2 to Ignore

February 28, 2025

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with...

Via StockStory

Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)

February 27, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom...

Via StockStory

Topics Artificial Intelligence

Which S&P500 stocks are moving on Tuesday? ↗

February 25, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday.

Via Chartmill

Explore the top gainers and losers within the S&P500 index in today's session. ↗

February 25, 2025

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

24 25 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.